Erschienen in:
29.10.2018 | ASO Author Reflections
ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer
verfasst von:
Stefano Andrianello, MD, Giovanni Marchegiani, MD, PhD, Roberto Salvia, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
The introduction of FOLFIRINOX
1 and nab-paclitaxel
2 radically changed the natural history of pancreatic ductal adenocarcinoma (PDAC). Soon after demonstrating the positive effect in improving survival in metastatic disease, several pieces of evidence about their use in the neoadjuvant setting for locally advanced and borderline-resectable PDAC have been collected.
3 In addition to the ability to reduce local disease burden, neoadjuvant therapy (NAT) has also been associated with improved surgical outcome. Patients undergoing pancreaticoduodenectomy (PD) after FOLFIRINOX, in particular, show an incredibly low rate of pancreatic fistula due to the fibrotic changes of the pancreatic stump found at surgery.
4 All these promising results are pushing towards increasingly widespread use of NAT, even in case of resectable PDAC. …